S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
Secure your stake in the Smart Home industry. (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable

Taysha Gene Therapies Stock Price, News & Analysis (NASDAQ:TSHA)

$1.79
-0.01 (-0.56%)
(As of 11/28/2023 ET)
Compare
Today's Range
$1.74
$1.85
50-Day Range
$1.33
$3.16
52-Week Range
$0.50
$3.89
Volume
2.90 million shs
Average Volume
2.02 million shs
Market Capitalization
$334.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.89

Taysha Gene Therapies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
229.0% Upside
$5.89 Price Target
Short Interest
Bearish
7.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Taysha Gene Therapies in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$163,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.69) to ($0.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

723rd out of 949 stocks

Biological Products, Except Diagnostic Industry

123rd out of 160 stocks


TSHA stock logo

About Taysha Gene Therapies Stock (NASDAQ:TSHA)

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

TSHA Stock Price History

TSHA Stock News Headlines

Taysha Gene Therapies Inc Ordinary Shares
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
A Preview Of Taysha Gene Therapies's Earnings
Taysha Discontinues Development Of TSHA-120 In Giant Axonal Neuropathy
See More Headlines
Receive TSHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/26/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TSHA
Fax
N/A
Employees
65
Year Founded
2020

Price Target and Rating

Average Stock Price Target
$5.89
High Stock Price Target
$10.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+229.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-166,010,000.00
Net Margins
-1,498.57%
Pretax Margin
-1,494.08%

Debt

Sales & Book Value

Annual Sales
$2.50 million
Book Value
$0.02 per share

Miscellaneous

Free Float
182,753,000
Market Cap
$334.66 million
Optionable
Not Optionable
Beta
0.13

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Sean P. NolanMr. Sean P. Nolan (Age 55)
    CEO & Chairman
    Comp: $674k
  • Dr. Sukumar Nagendran M.D. (Age 56)
    President, Head of Research & Development and Director
    Comp: $619.1k
  • Mr. Kamran  Alam CPAMr. Kamran Alam CPA (Age 45)
    M.B.A., CFO & Corporate Secretary
    Comp: $703.61k
  • Hayleigh Collins
    Director & Head of Corporate Communications
  • Ms. Tracy M. Porter SPHR
    Chief People Officer
  • Mr. Frederick Porter Ph.D.
    Chief of Staff & Technical Operations Officer
  • Ms. Emily McGinnis M.P.H.
    Chief Patient Advocacy & External Affairs Officer
  • Mr. Sean McAuliffe
    Chief Business Officer
  • Dr. Steven Gray Ph.D.
    Chief Scientific Advisor of UT Southwestern Gene Therapy Program
  • Berge Minassian M.D.
    Chief Medical Advisor of UT Southwestern Gene Therapy Program














TSHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Taysha Gene Therapies stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSHA shares.
View TSHA analyst ratings
or view top-rated stocks.

What is Taysha Gene Therapies' stock price target for 2024?

11 brokerages have issued 1-year target prices for Taysha Gene Therapies' stock. Their TSHA share price targets range from $3.00 to $10.00. On average, they expect the company's stock price to reach $5.89 in the next twelve months. This suggests a possible upside of 229.0% from the stock's current price.
View analysts price targets for TSHA
or view top-rated stocks among Wall Street analysts.

How have TSHA shares performed in 2023?

Taysha Gene Therapies' stock was trading at $2.26 at the start of the year. Since then, TSHA stock has decreased by 20.8% and is now trading at $1.79.
View the best growth stocks for 2023 here
.

Are investors shorting Taysha Gene Therapies?

Taysha Gene Therapies saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 13,950,000 shares, an increase of 42.9% from the October 31st total of 9,760,000 shares. Based on an average trading volume of 2,490,000 shares, the days-to-cover ratio is presently 5.6 days.
View Taysha Gene Therapies' Short Interest
.

When is Taysha Gene Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our TSHA earnings forecast
.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.02) by $0.33. Taysha Gene Therapies had a negative net margin of 1,498.57% and a negative trailing twelve-month return on equity of 1,790.06%. During the same period last year, the company posted ($1.28) earnings per share.

When did Taysha Gene Therapies IPO?

(TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager.

Who are Taysha Gene Therapies' major shareholders?

Taysha Gene Therapies' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (13.12%), RA Capital Management L.P. (9.88%), RTW Investments LP (9.04%), Acuta Capital Partners LLC (2.05%), Kynam Capital Management LP (1.76%) and Polar Capital Holdings Plc (1.35%). Insiders that own company stock include John A Stalfort III, Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad.
View institutional ownership trends
.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TSHA) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -